Results 81 to 90 of about 169,027 (313)

Role of Monoclonal Antibodies in the Treatment of Asthma

Canadian Respiratory Journal, 2013
BACKGROUND: Patients with severe refractory asthma represent a small subset of the asthmatic population (between 5% and 10% of all patients) but are the greatest burden to the health care system.
Paul M O’Byrne
doaj   +1 more source

A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms

Frontiers in Molecular Biosciences, 2020
As human Tau undergoes pathologically relevant post-translational modifications when expressed in yeast, the use of humanized yeast models for the generation of novel Tau monoclonal antibodies has previously been proven to be successful.
Joke Verelst, Nick Geukens, Sabiha Eddarkaoui, Dorien Vliegen, Elien De Smidt, Joëlle Rosseels, Vanessa Franssens, Sofie Molenberghs, Cindy Francois, Erik Stoops, Maria Bjerke, Maria Bjerke, Sebastiaan Engelborghs, Sebastiaan Engelborghs, Mohamed Laghmouchi, Sofie Carmans, Luc Buée, Eugeen Vanmechelen, Joris Winderickx, Debby Thomas   +19 more
doaj   +1 more source

Sortilin‐Mediated Rapid, Precise and Sustained Degradation of Membrane Proteins via mRNA‐Encoded Lysosome‐Targeting Chimera

Advanced Science, EarlyView.
The study identified sortilin as a promising LTR, enabling targeted degradation of oncogenic proteins through an mRNA‐encoded MedTAC strategy. In a mouse model, MedTACPTK7 reduced PTK7 by up to 80%, extended survival, and showed excellent pharmacokinetics without toxicity, providing a scalable platform for targeted therapies.
Xin Chang, Xinyu Qiu, Xiaoning Tong, Shaoju Gan, Weicheng Yi, Sitao Xie, Xiangsheng Liu, Chao Zuo, Weihong Tan   +8 more
wiley   +1 more source

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. [PDF]

, 2017
BackgroundThe CXCR4-CXCL12 axis plays an important role in the chronic lymphocytic leukemia (CLL)-microenvironment interaction. Overexpression of CXCR4 has been reported in different hematological malignancies including CLL.
Amaya-Chanaga, Carlos I, Amine, Ale-Ali, Castro, Januario E, Choi, Michael Y, Fantin, Valeria R, Gu, Yin, Hallin, Max, Huser, Nanni, Kashyap, Manoj K, Kipps, Thomas J, Kumar, Deepak, Lindquist, Kevin, Liu, Shu-Hui, Pernasetti, Flavia, Rassenti, Laura Z, Simmons, Brett, Smeal, Tod, Yafawi, Rolla, Zhang, Cathy   +18 more
core   +4 more sources

Rational Design and Organoid‐Based Evaluation of a Cocktail CAR‐γδ T Cell Therapy for Heterogeneous Glioblastoma

Advanced Science, EarlyView.
A novel “prof” cocktail therapy is designed. It screens antigens, selects personalized antigen panels, engineers optimized CAR‐Vδ1 T cells, and tests in patient‐derived GBM organoids, offering hope for effective CAR‐T drugs against heterogeneous solid tumors. Abstract Various challenges, including tumor heterogeneity and inadequate T cell infiltration,
Guidong Zhu, Zhongzheng Sun, Yingchao Liu, Jiang Liu, Linpei Guo, Guojing Pei, Ying Jiang, Baowang Miao, Zhen Li, Ping Zhang, Dongqi Tang, Wen Zhang, Chengwei Wang   +12 more
wiley   +1 more source

Primary malignant melanoma of the uterine cervix treated with pembrolizumab after radical surgery: a case report and literature review [PDF]

Obstetrics & Gynecology Science, 2018
Malignant melanoma of the genital tract is a rare disease that is usually diagnosed by chance. When a definite diagnosis is delayed, the prognosis is very poor without standardized treatment. Herein, we describe a 40-year-old patient who presented with a
Myeong Seon Kim, Chel-Hun Choi, Tae-Joong Kim, Jeong-Won Lee, Jeeyun Lee, Duk-Soo Bae, Byoung-Gie Kim   +6 more
doaj   +1 more source

Applications in Which Aptamers Are Needed or Wanted in Diagnostics and Therapeutics

Pharmaceuticals, 2022
One strategy for bringing aptamers more into the mainstream of biomedical diagnostics and therapeutics is to exploit niche applications where aptamers are truly needed or wanted for their innate differences versus antibodies.
John G. Bruno
doaj   +1 more source

Potent Cross‐neutralizing Antibodies Reveal Vulnerabilities of Henipavirus Fusion Glycoprotein

Advanced Science, EarlyView.
Hendra and Nipah viruses (HNVs) pose significant threats to global health. This work reports potent cross‐neutralizing antibodies targeting the fusion glycoprotein (F) and reveals shared features of these antibodies and vulnerabilities of F, thereby guiding the rational design of countermeasures against HNVs and similar pathogens.
Yi Ren, Pengfei Fan, Xinghai Zhang, Ting Fang, Zhengshan Chen, Yanfeng Yao, Xiangyang Chi, Guanying Zhang, Xiaofan Zhao, Bingjie Sun, Fangxu Li, Zixuan Liu, Zhenwei Song, Baoyue Zhang, Cheng Peng, Entao Li, Yilong Yang, Jianmin Li, Sandra Chiu, Changming Yu   +19 more
wiley   +1 more source

γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody

Haematologica, 2011
Background Anti-CD20 monoclonal antibodies are major therapeutic agents for patients with follicular lymphoma and work through complement-mediated cytotoxicity and antibody-dependent cellular cytotoxicity.
Mounia Sabrina Braza, Bernard Klein, Geneviève Fiol, Jean-François Rossi   +3 more
doaj   +1 more source

Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance [PDF]

arXiv, 2021
The latest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron (B.1.1.529) has ushered panic responses around the world due to its contagious and vaccine escape mutations. The essential infectivity and antibody resistance of the SARS-CoV-2 variant are determined by its mutations on the spike (S) protein receptor-binding domain (
arxiv